A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors

被引：0

作者：

LoRusso, P. ^{[1
]}

Keedy, V. ^{[2
]}

Yee, L. ^{[3
]}

Oliveira, M. ^{[3
]}

Rizvi, N. ^{[4
]}

Berlin, J. ^{[2
]}

Jin, X. ^{[5
]}

Hettmann, T. ^{[6
]}

Copigneaux, C. ^{[7
]}

Beaupre, D. ^{[8
]}

机构：

[1] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Phase Serv 1, Detroit, MI USA

[2] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA

[3] NW Med Specialties, Med Oncol, Tacoma, WA USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[5] Daiichi Sankyo, Biostat, Edison, NJ USA

[6] U3 Pharma GmbH, Oncol Res, Munich, Germany

[7] Daiichi Sankyo, Clin Dev, Edison, NJ USA

[8] Amgen Inc, Early Dev, Thousand Oaks, CA 91320 USA

来源：

EJC SUPPLEMENTS | 2010年 / 8卷 / 07期

关键词：

D O I：

10.1016/S1359-6349(10)71939-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：76 / 76

页数：1